

Cardiovascular Risk Assessment in Non-Alcoholic Fatty Liver Disease: Association of Sleep Disturbance with Cardiovascular Risk

Kavita Bai^{1*}, Jawaid Ahmed Zai², Feroz S Memon³, Zaib- Un-Nisa Mughal⁴

ABSTRACT

OBJECTIVE: To assess the association between sleep disturbance and CVD risk in patients of Non-Alcoholic Fatty Liver Disease.

METHODOLOGY: This cross-sectional study was conducted at the University of Sindh, Jamshoro, Sindh, Pakistan, from August 2023 to July 2024. We used purposive, non-probability sampling to recruit 196 NAFLD patients who met the selection criteria. NAFLD was diagnosed on ultrasound following non-invasive guidelines of liver disease (NILDA). Patients with viral hepatitis, chronic liver disease other than fatty changes, malignancy, thyroid dysfunction, and alcohol were excluded from this study. Sleep quality was assessed using the Insomnia Severity Index, and the 10-year cardiovascular (CVD) risk was quantified using the Framingham risk score. The data were analyzed using IBM SPSS version 27.0, and p -values < 0.05 were considered statistically significant.

RESULTS: Among 196 patients of NAFLD, 19.9% had normal sleep, 16.8% had subthreshold insomnia, 39.3% had moderate insomnia, and 24.0% had severe insomnia. The Insomnia Severity Index was positively correlated with 10-year CVD risk (p -value < 0.01). In unadjusted analysis, sleep disturbance in NAFLD patients was significantly associated with higher CVD risk (COR = 1.19, 95% CI: 1.10–1.29, $p < 0.01$). After adjusting for potential confounders, sleep disturbance remained independently associated with higher CVD risk. (AOR = 1.15, 95% CI: 1.05–1.27, $p < 0.01$).

CONCLUSION: It is concluded that there is a higher 10- year CVD risk in NAFLD patients with sleep disturbance

KEY WORDS: Cardiovascular disease risk, Framingham risk score, Insomnia severity index, Nonalcoholic fatty liver disease, sleep disturbance

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) encompasses liver dysfunctions occurring due to fatty changes in liver parenchyma, progressing to non-alcoholic steatohepatitis and worsening to fibrotic changes. As the disease advances, it may lead to cardiovascular disease (CVD)¹. Globally, the prevalence of NAFLD is 25%, and it has been seen as the most common cause of cirrhosis and hepatocellular carcinoma². NAFLD is increasingly recognized as a major global health problem. It has been observed as frequently intertwined with diabetes, metabolic syndrome and obesity.

In comparison to the general population, the prevalence of CVD has been observed to be augmented in NAFLD patients. Therefore, CVD risk assessment is essential in these patients. Pre-clinical effects of NAFLD on the heart include both metabolic

and structural alterations, eventually progressing to myocardial dysfunctions³. The incidence of NAFLD has been observed to be higher among the young age group, contributing to the risk of CVD in young people⁴. Meanwhile, proper sleep plays an important role in health, and disturbances in the sleep-wake cycle can trigger a cascade of inflammatory processes that contribute to the development of liver dysfunction and, for the most part, the development and progression of NAFLD. Patients with liver dysfunction have been found to suffer from sleep disturbances, affecting their quality of life⁵. Poor sleep has also been considered as one of the risk factors for developing NAFLD⁶. Long-lasting sleep deprivation or poor sleep quality aggravates oxidative stress, and breathing obstructions in sleep apnea reduce oxygen intake and accelerate the progression of fatty liver to steatohepatitis. Insomnia leads to sympathetic dominance, which increases the accumulation of oxygen-free radicals and intensifies the oxidative stress response. Oxidative stress further inhibits normal sleep by increasing neuronal activity and causing cell damage⁷. NAFLD is asymptomatic until it advances to fibrosis, so many patients are identified only at advanced stages⁸. Sleep disturbance increases insulin resistance in peripheral tissues such as muscle and adipose tissue, with elevated cortisol levels due to increased hypothalamic–pituitary–adrenal axis activity.

¹PhD Scholar, University of Sindh, Jamshoro, Sindh, Pakistan

²Associate Professor, Department of Physiology and MLT, University of Sindh, Jamshoro, Sindh, Pakistan

³Vice Chancellor and Professor of Cardiology, University of Modern Sciences, Tando Muhammad Khan, Sindh, Pakistan

⁴Assistant Professor, Department of Physiology and MLT, University of Sindh, Jamshoro, Sindh, Pakistan

Correspondence: baidrkavita@gmail.com

doi: 10.22442/jlumhs.2026.01438

Received: 16-12-2025

Revised: 17-02-2026

Accepted: 04-03-2026

Online First: 16-04-2026



In contrast, activation of the sympatho-adrenomedullary system increases circulating catecholamines. This autonomic imbalance reduces vagal tone, causes vasoconstriction, and increases heart rate, blood pressure, and myocardial load. Disturbed sleep can alter appetite-regulating hormones, i.e., decreasing leptin and increasing ghrelin, which can promote weight gain. Chronic insomnia leads to 45% greater odds of developing CVD⁹.

Fatty liver disease is not confined to the liver. It may progress to cardiovascular dysfunction, and insomnia has been identified as increasing the risk of developing NAFLD to 13%¹⁰. However, many studies have evaluated sleep disturbance in the general population and obese individuals, but not specifically in NAFLD patients. A few studies have studied sleep as a risk factor for NAFLD, but there is limited evidence about the association of sleep with CVD risk in NAFLD. Better-quality sleep may reduce CVD risk in NAFLD. There has been a lack of structured assessment of insomnia severity using validated instruments such as the Insomnia Severity Index (ISI) in NAFLD patients¹¹. The role of sleep disturbance as a CVD risk predictor has never been studied specifically in NAFLD patients. Furthermore, most NAFLD studies focus on hepatic outcomes categorized by biopsy findings (simple steatosis, NASH, and fibrosis) without stratifying NAFLD patients by sleep quality. This study categorizes NAFLD patients based on the International Sleep Disorders Disordered Personality (ISI) scale to measure sleep disturbance. It then estimates the 10-year CVD risk score (%) using the Framingham CVD risk score to assess the association between sleep disturbance and CVD risk in patients with NAFLD¹².

METHODOLOGY

This cross-sectional study was conducted at the University of Sindh, Jamshoro, Sindh, Pakistan. We used non-probability, purposive sampling of 196 NAFLD patients who met the selection criteria. The study was conducted from August 2023 to July 2024. NAFLD, after approval from the Institutional Advanced Studies and Research Board, letter No. DRGS 1896. Ultrasound and biological parameters were used to diagnose NAFLD, following the NILDA (Non-invasive Liver Disease Assessment) guidelines of the AASLD (American Association for the Study of Liver Diseases). Patients with viral hepatitis, chronic liver disease other than fatty changes, malignancy, thyroid dysfunction, and alcohol were excluded from this study. The detailed history was taken from the patients about their age, gender, sleep disturbances, medications taken previously, diabetes, taking antihypertensive medicines previously and about smoking/ taking alcohol.

The 10-year CVD risk (%) was quantified using the Framingham risk score. To calculate the Framingham-based CVD risk%, the following parameters were

used: age, gender, HDL, total cholesterol, smoking status, hypertension, and diabetic/non-diabetic status. NAFLD patients were considered hypertensive when their systolic BP was ≥ 140 mmHg and/or diastolic BP was ≥ 90 mmHg as determined by the mean of the second and third readings and/or by taking antihypertensive medication.

After informed consent, their BP was recorded using a standard digital sphygmomanometer (OMRON Healthcare, Kyoto, Japan). Participants were asked to sit comfortably, with their backs supported and arms resting at heart level for BP checks. Their BP was measured after ensuring they had not consumed caffeine, smoked, or exercised within 30 minutes of the measurement. They were asked about their smoking, diabetes medical history and about taking any medications. For lipid profile, an IV blood sample was obtained after taking all aseptic measures and obtaining informed consent. In the lipid profile, HDL and total cholesterol levels were measured on Roche/Hitachi cobas c systems using a c311 analyzer based on the calorimetric principle. The sleep disturbance was assessed using the validated self-reported Insomnia Severity Index (ISI), a questionnaire developed by Bestein CH 2001¹¹. ISI is answered on a 5-point Likert scale, yielding scores in the range of 0 -28. Higher scores are suggestive of the severity of sleep disturbances.

The data were analyzed using IBM SPSS version 27.0, and p-values < 0.05 were considered statistically significant. Numeric variables are presented as means with standard deviations. The qualitative data are presented as absolute frequencies (n) and relative frequencies (%). A Pearson correlation was performed to assess the relationship between ISI and the 10-year CVD risk score. Logistic regression was performed to find the association of sleep disturbance in NAFLD with 10 -year CVD risk.

RESULTS

In the present study, the mean age of NAFLD individuals was 38.16 ± 5.63 years; 126 were males, and 70 were females. **Table I** shows the baseline characteristics (BMI, BP, WHR, ISI, smoking, fasting blood sugar, and lipid profile of the study population.

The levels of Sleep disturbance were evaluated using the ISI in NAFLD patients. Among 196 patients of NAFLD, 19.9% were found to have normal sleep, 16.8% with subthreshold insomnia, 39.3% with moderate severity insomnia and 24.0 % with severe insomnia, as shown in **Table II**.

The mean and SD of 10-year CVD risk (%) were 8.96 ± 6.7 , 8.01 ± 4.1 , 10.08 ± 7.1 , and 16.89 ± 9.0 among NAFLD individuals with normal sleep, subthreshold insomnia, moderate-severity insomnia, and severe insomnia, respectively. We compared 10-year CVD risk (%) across sleep disturbance levels using one-way analysis of variance ($p < 0.01$). As shown in **Table III**.

Table I: Baseline features of study population (n=196)

	Mean	Std. Deviation	n(%)
Age (years)	38.16	5.63	--
Gender			
Male	--	--	126(64.3)
Female	--	--	70(35.7)
Systolic BP(mmHg)	123.47	6.14	--
Diastolic BP(mmHg)	80.35	3.95	--
BMI	25.79	2.17	--
WHR	0.89	0.08	--
ISI	15.62	7.80	--
Fasting blood sugar (mmol/l)	3.28	0.98	--
HDL cholesterol(mmol/l)	0.91	0.21	--
Total cholesterol(mmol/l)	5.60	1.06	--
Smoking status			
Smoker	--	--	68(34.7)
Non smoker	--	--	128(65.3)

Table II: Levels of Sleep disturbance (according to ISI) in NAFLD patients (n=196)

Levels of Sleep Disturbance	Absolute Frequency	Relative frequency (%)
0 to 7(normal sleep)	39	19.9
8-14(Subthreshold insomnia)	33	16.8
15-21(Moderate severity insomnia)	77	39.3
22-28 (severe insomnia)	47	24.0
Total	196	100.0

Table III: Comparison of 10-year CVD risk % according to levels of sleep disturbance in NAFLD patients (n=196)

Levels of sleep disturbance (ISI)	n	10-year CVD Risk (%)		f- value	p- value
		Mean±Std. Dev	Std. Error of mean		
0 to 7(normal sleep)	39	8.96±6.7	1.0	13.7	<0.01*
8-14(Subthreshold insomnia)	33	8.01±4.1	0.7		
15-21(Moderate severity insomnia)	77	10.08±7.1	0.8		
22-28 (severe insomnia)	47	16.89±9.0	1.3		

*Shows statistically significant, p-value<0.05

Pearson's correlation analysis was performed to assess the relationship between the 10-year CVD risk score (%) and ISI among NAFLD patients. A statistically significant positive correlation was observed, indicating that higher ISI scores were associated with increased CVD risk (r-value = 0.31, p-value < 0.01). As shown in **Table IV**.

Table IV: Correlation between ISI and 10-year CVD risk score in NAFLD patients (n=196)

ISI	10-year CVD risk	
	r- value	0.31**
	p-value	<0.01

To examine the association between sleep disturbance and CVD risk among NAFLD patients, binary logistic regression analysis was performed. The original three CVD risk categories were dichotomized into two groups: the lower-risk category was coded as 0, and the intermediate- and high-risk categories were combined and coded as 1 (the higher CVD risk group). Although CVD risk was initially categorized into three ordered groups (low, intermediate, and high), a binary logistic regression was performed after dichotomizing the outcome variable. We combined the intermediate- and high-risk categories to create a clinically meaningful "higher CVD risk" group. In unadjusted analysis, sleep disturbance was significantly associated with higher CVD risk (COR = 1.19, 95% CI: 1.10–1.29, p < 0.01). After adjusting for potential confounders, including age, BMI, WHR, hemoglobin A1c, and fasting blood glucose, sleep disturbance remained independently associated with higher CVD risk among NAFLD patients (AOR = 1.15, 95% CI: 1.05–1.27, p < 0.01). As shown in **Table V**.

Table V: Logistic regression for association of insomnia severity with 10-year CVD risk (%) in NAFLD

	COR (95% CI)	p-value	AOR (95% CI)	p-value
ISI	1.19 (1.10-1.29)	<0.001	1.15 (1.05-1.27)	0.002

COR=Crude odds ratio, AOR=Adjusted odds ratio, AOR adjusted for age, BMI, WHR, fasting blood glucose and haemoglobin A1c

DISCUSSION

Sleep disturbance can contribute to worsening of illness, as well as lead to worsening of the condition, like CVD risk in NAFLD. This research study has utilized the ISI to assess the level of sleep disturbance, developed by Bestein CH 2001¹¹, and the CVD risk % was quantified using the Framingham-based CVD risk score¹², which used age, gender, HDL, total cholesterol, smoking status, hypertensive status, and diabetic/non-diabetic status. The present study has revealed that the sleep pattern in NAFLD patients is disturbed in the majority of patients. In the present study, in NAFLD, 39.3% were found to have

moderate severity insomnia and 24.0 % with severe insomnia. Supporting our study, Zarean E 2023¹³ have highlighted in their study that insomnia affects the quality of life as well as worsens the prognosis in NAFLD patients. Similarly, Yu L et al.¹⁴ found significant differences in sleep patterns among NAFLD patients. According to them, the most prevalent pattern is daytime sleepiness, with insomnia at night occurring in NAFLD patients. Further, they suggested that addressing sleep patterns in NAFLD patients may slow disease progression. Sun Z 2023¹⁵ have depicted an augmented risk of NAFLD among individuals having sleep disturbance, so depicting the insomnia might serve as an early predictor of developing NAFLD and therefore early identification can prevent progression to complications like CVD risk. Yu JH 2015¹⁶ have revealed the relationship between NAFLD and obstructive sleep apnea-related insomnia. Spiegel K 2009¹⁷ reported that management of insomnia has a beneficial impact on glucose metabolism; they advised screening for sleep patterns among people with metabolic dysfunctions. Wei YT 2020¹⁸ and Takahashi A 2020¹⁹ have also found a significant association of NAFLD with insomnia. Mir MH 2013²⁰ have found from NHANES participants that insomnia is more common in people with NAFLD. Previous studies support the link of NAFLD and sleep disturbance, but they have not quantified the CVD risk in such patients with sleep disturbance. To fill this gap, the present study described sleep patterns by NAFLD severity and assessed CVD risk using Framingham scoring based on these patterns. In the present study, the mean 10-year CVD risk was $10.08 \pm 7.1\%$ in moderate-severity insomnia and $16.89 \pm 9.0\%$ in severe insomnia. According to Bu LF 2024²¹, dysregulation in circadian rhythm owing to insomnia has been linked to the development of NAFLD. Melatonin plays a role in sleep, and it has been shown to prevent hepatic damage by inhibiting inflammation, apoptosis, and oxidative stress²². This way, sleep contributes to the prevention of worsening of NAFLD. If NAFLD coexists with insomnia, it facilitates liver inflammation, insulin resistance, and increases cortisol and cytokine release^{7,23}. Supporting our study, Wang Z et al.²⁴ have revealed that insomnia contributes to worsening of hepatic steatosis and CVD by dysregulation of lipid metabolism in the liver and atherosclerosis²⁴. Therefore, both contribute to increased 10-year CVD risk. According to them, there is sympathetic overstimulation in NAFLD, which contributes to CVD dysfunction. Present study has found that sleep disturbance as the significantly associated 10-year CVD risk in NAFLD without adjusting for confounding factors (COR=1.19, CI: 1.10-1.29 $p < 0.01$) and after adjusting for confounding factors like BMI, age, WHR, hemoglobin a1c and fasting blood glucose, sleep disturbance is significantly associated with 10- year CVD risk among NAFLD patients (AOR=1.15, CI: 1.05

-1.27, $p < 0.01$). Supporting the present study, Addo PNO et al.²⁵ found that disturbed sleep patterns are linked with abnormal triglyceride levels and worse glycemic control, which may contribute to CVD risk. They suggest sleep as a modifiable CVD risk factor to maintain metabolic balance. Supporting the present study's findings, Marjot T 2021⁵ have also suggested that sleep disturbance in NAFLD initiates an inflammatory cascade, alters metabolism, disrupts the sleep-wake cycle and melatonin levels, and contributes to worsening of liver function and increased CVD risk in fatty liver conditions. In contrast to the present study, one study has found that sleeping excessively can even increase the CVD risk, mainly in those suffering from some chronic condition like NAFLD; this might be attributable to less physical activity in such individuals²⁶. Supporting the findings of our study, Cao X 2016²⁷ found that poor sleep quality in NAFLD patients was associated with a significantly higher prevalence of arterial stiffness, independent of several confounders. In their study, sleep duration of ≤ 6 hours was associated with a higher prevalence of arterial stiffness (OR 2.14) than ≥ 8 hours. This study suggests the need to help individuals with NAFLD obtain adequate quality and quantity of sleep to effectively control cardiometabolic risk factors and prevent progression of atherosclerosis in high-risk populations.

CONCLUSION

It is concluded that there is a higher 10-year CVD risk in NAFLD patients with sleep disturbance.

Future studies: Studies can be conducted to explore the melatonin levels in NAFLD patients with increased CVD risk.

Ethical Permission: University of Sindh, Jamshoro, Pakistan, ERC approval letter No. DRGS/1894.

Disclaimer: This article is part of PhD work at the University of Sindh, Jamshoro.

Conflict of interest: There is no conflict of interest between the authors.

Financial Disclosure / Grant Approval: No funding agency was involved in this research.

Data Sharing Statement: The corresponding author can provide the data proving the findings of this study on request. Privacy or ethical restrictions bound us from sharing the data publicly.

AUTHOR CONTRIBUTION

Bai K: Conception of work, data acquisition, interpretation and data analysis, critical review, and finalizing the draft

Zai JA: Interpretation of data, valuable suggestions for improvement, critical review, finalizing the draft.

Memon FS: Critical review, interpretation and acquisition of data, valuable feedback.

Mughal ZUN: Data collection, writing discussions, literature search, final approval for critical review.

REFERENCES

1. Park Y, Ko KS, Rhee BD. Non-Alcoholic Fatty Liver Disease (NAFLD) Management in the Community. *Int J Mol Sci.* 2025; 26(6): 2758. doi:10.3390/ijms26062758.
2. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. *Lancet.* 2021; 397(10290): 2212-2224. doi: 10.1016/S0140-6736(20)32511-3.
3. Bisaccia G, Ricci F, Mantini C. Nonalcoholic fatty liver disease and cardiovascular disease phenotypes. *SAGE Open Med.* 2020; 8: 2050312120933804. doi: 10.1177/2050312120933804.
4. Wang JJ, Zheng Z, Zhang Y. Association of overweight/obesity and overweight/obesity-related metabolic dysfunction-associated steatotic liver disease in young adults with coronary artery calcification later in life. *Diabetes Obes Metab.* 2024; 26(9): 3860-3867. doi: 10.1111/dom.15733.
5. Marjot T, Ray DW, Williams FR, Tomlinson JW, Armstrong MJ. Sleep and liver disease: a bidirectional relationship. *Lancet Gastroenterol Hepatol.* 2021; 6(10): 850-863. doi: 10.1016/S2468-1253(21)00169-2.
6. Chang X, Guo C, Zhou H, Liu L. Impact of rumination on sleep quality among patients with non-alcoholic fatty liver disease: a moderated mediation model of anxiety symptoms and resilience. *BMC Psychiatry.* 2023; 23(1): 84. doi: 10.1186/s12888-023-04572-8.
7. Wang D, Zhang X, Cai Y, Dong H, Zhang Y. Multidimensional sleep impairment predicts steatotic liver disease spectrum risk. *Sci Rep.* 2025; 15(1): 10405. Published Online 2025 Mar 26. doi: 10.1038/s41598-025-95336-9.
8. Piazzolla VA, Mangia A. Noninvasive Diagnosis of NAFLD and NASH. *Cells.* 2020; 9(4): 1005. doi: 10.3390/cells9041005.
9. Direksunthorn T. Sleep and Cardiometabolic Health: A Narrative Review of Epidemiological Evidence, Mechanisms, and Interventions. *Int J Gen Med.* 2025; 18: 5831-5843. doi: 10.2147/IJGM.S563616.
10. Wijarnpreecha K, Thongprayoon C, Panjawatanan P, Ungprasert P. Insomnia and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. *J Postgrad Med.* 2017; 63(4): 226-231. doi: 10.4103/jpgm.JPGM_140_17.
11. Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. *Sleep Med.* 2001; 2(4):297-307. doi:10.1016/s1389-9457(00)00065-4.
12. D'Agostino RB Sr, Vasan RS, Pencina MJ. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation.* 2008; 117(6): 743-753. doi: 10.1161/CIRCULATIONAHA.107.699579.
13. Zarean E, Looha MA, Amini P. Sleep characteristics of middle-aged adults with non-alcoholic fatty liver disease: findings from the Shahrekord PERSIAN cohort study. *BMC Public Health.* 2023; 23: 312. <https://doi.org/10.1186/s12889-023-15251-4>.
14. Yu L, Lin C, Chen X, Teng Y, Zhou S, Liang Y. A Meta-Analysis of Sleep Disorders and Nonalcoholic Fatty Liver Disease: Potential Causality and Symptom Management. *Gastroenterol Nurs.* 2022; 45(5): 354-363. doi: 10.1097/SGA.0000000000000658.
15. Sun Z, Ji J, Zuo L. Causal relationship between nonalcoholic fatty liver disease and different sleep traits: a bidirectional Mendelian randomized study. *Front Endocrinol (Lausanne).* 2023; 14: 1159258. doi: 10.3389/fendo.2023.1159258.
16. Yu JH, Ahn JH, Yoo HJ. Obstructive sleep apnea with excessive daytime sleepiness is associated with non-alcoholic fatty liver disease regardless of visceral fat. *Korean J Intern Med.* 2015; 30(6): 846-855. doi: 10.3904/kjim.2015.30.6.846.
17. Spiegel K, Tasali E, Leproult R, Van Cauter E. Effects of poor and short sleep on glucose metabolism and obesity risk. *Nat Rev Endocrinol.* 2009; 5(5): 253-261. doi: 10.1038/nrendo.2009.23.
18. Wei YT, Lee PY, Lin CY. Non-alcoholic fatty liver disease among patients with sleep disorders: a Nationwide study of Taiwan. *BMC Gastroenterol.* 2020; 20(1): 32. doi: 10.1186/s12876-020-1178-7.
19. Takahashi A, Anzai Y, Kuroda M. Effects of sleep quality on non-alcoholic fatty liver disease: a cross-sectional survey. *BMJ Open.* 2020; 10(10): e039947. Published Online 2020 Oct 29. doi: 10.1136/bmjopen-2020-039947.
20. Mir HM, Stepanova M, Afendy H, Cable R, Younossi ZM. Association of Sleep Disorders with Nonalcoholic Fatty Liver Disease (NAFLD): A Population-based Study. *J Clin Exp Hepatol.* 2013; 3(3): 181-185. doi: 10.1016/j.jceh.2013.06.004.
21. Bu LF, Xiong CY, Zhong JY. Non-alcoholic fatty liver disease and sleep disorders. *World J Hepatol.* 2024; 16(3): 304-315. doi: 10.4254/wjh.v16.i3.304.
22. Abdi S, Abbasinazari M, Ataei S, Khanzadeh-Moghaddam N, Keshvari N. Benefits and Risks of Melatonin in Hepatic and Pancreatic Disorders; A Review of Clinical Evidences. *Iran J Pharm Res.* 2021; 20(3): 102-109. doi: 10.22037/ijpr.2020.114477.14872.
23. Yang X, Zhuo S, Zhuang H. Interaction between the systemic immune-inflammation index and trouble sleeping in nonalcoholic fatty liver disease: a cross-sectional study of the NHANES 2005–2018 data. *J Health Popul Nutr.* 2024; 43: 175.

- <https://doi.org/10.1186/s41043-024-00670-9>.
24. Wang Z, Liang X, Lu Y, Jiang T, Aji T, Aimulajiang K et al. Insomnia promotes hepatic steatosis in rats possibly by mediating sympathetic overactivation. *Front Physiol.* 2021 Sep 24; 12: 734009.
 25. Addo PNO, Mundagowa PT, Zhao L, Kanyangarara M, Brown MJ, Liu J. Associations between sleep duration, sleep disturbance and cardiovascular disease biomarkers among adults in the United States. *BMC Public Health.* 2024 Apr 2; 24(1): 947. doi: 10.1186/s12889-024-18381-5.
 26. Qasrawi SO, BaHammam AS. Role of Sleep and Sleep Disorders in Cardiometabolic Risk: A Review and Update. *Curr Sleep Med Rep.* 2024; 10: 34–50. doi: 10.1007/s40675-024-00276-x.
 27. Cao X, Zhou J, Yuan H. Association between sleep condition and arterial stiffness in Chinese adult with nonalcoholic fatty liver disease. *J Thromb Thrombolysis.* 2016; 42: 127–134. <https://doi.org/10.1007/s11239-016-1356-1>.

